Biotech Firm Pits Its Actives Against Leading Skin Lighteners On Market
This article was originally published in The Rose Sheet
Executive Summary
Unlike skin-lightening ingredient arbutin, which releases potentially carcinogenic hydroquinone, Sirona Biochem Corp.’s TFC-849 and TFC-723 compounds are stable and do not break down in the body. They’re more effective tyrosinase inhibitors as well, the Canadian biotech firm says.